GlassScriptPhysician profile
Jamie J Graves
NPI 1811295629
$7,149.53
in general payments reported to CMS, 2019-2025
17 companies · $2,593 in 2025
The $2,593 reported for 2025 was more than what 95% of Psychiatric/Mental Health (Nurse Practitioner) providers received nationally (typical 2025 total: $257).
See the full distribution for Psychiatric/Mental Health (Nurse Practitioner)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,241 · 2022: $407 · 2023: $1,204 · 2024: $1,704 · 2025: $2,593.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,302 · Education: $200.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,301.92 |
| Education | $199.64 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $1,040.64 | 2021-2025 | Caplyta |
| Otsuka America Pharmaceutical, INC. | $930.21 | 2021-2025 | Rexulti, Abilify Asimtufii, Abilify Maintena |
| Teva Pharmaceuticals USA, INC. | $898.04 | 2021-2025 | Austedo Xr, Uzedy, Austedo Xr |
| Janssen Pharmaceuticals, INC | $792.69 | 2022-2025 | Invega Sustenna, Invega Trinza, Spravato |
| Alkermes, INC. | $675.53 | 2021-2025 | Aristada, Lybalvi, Aristada Initio |
| Abbvie INC. | $622.16 | 2021-2025 | |
| Lundbeck LLC | $528.71 | 2021-2025 | Abilify Maintena, Rexulti |
| Neurocrine Biosciences, INC. | $424.52 | 2024-2025 | Ingrezza |
| Supernus Pharmaceuticals, INC. | $236.94 | 2021-2025 | Qelbree |
| E.R. Squibb & Sons, L.L.C. | $202.67 | 2024-2025 | Cobenfy |
| Axsome Therapeutics, INC. | $182.07 | 2023-2025 | Auvelity |
| Vanda Pharmaceuticals INC. | $174.92 | 2024-2025 | Fanapt, Hetlioz |
| Sunovion Pharmaceuticals INC. | $158.40 | 2021-2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $100.52 | 2021-2025 | Trintellix |
| Indivior INC. | $88.73 | 2023 | Perseris |
Show all 17 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Adlon Therapeutics L.P. | $68.03 | 2021 | |
| Almatica Pharma LLC | $24.75 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jamie Graves listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.